184 related articles for article (PubMed ID: 16825385)
21. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre.
Quindós G; Sánchez-Vargas LO; Villar-Vidal M; Eraso E; Alkorta M; Hernández-Almaraz JL
Int J Antimicrob Agents; 2008 Mar; 31(3):266-71. PubMed ID: 18054468
[TBL] [Abstract][Full Text] [Related]
22. A study of dermatophytes and their in-vitro antifungal sensitivity.
Sumana MN; Rajagopal V
Indian J Pathol Microbiol; 2002 Apr; 45(2):169-72. PubMed ID: 12696733
[TBL] [Abstract][Full Text] [Related]
23. Presence of dermatophytes on the nails of tinea capitis patients. Prospective study in the area of Sfax (Tunisia).
Cheikhrouhou F; Makni F; Sellami H; Besbes M; Ayadi A
Mycoses; 2003 Sep; 46(8):334-5. PubMed ID: 12950904
[TBL] [Abstract][Full Text] [Related]
24. [In vitro antifungal activity of voriconazole against dermatophytes and superficial isolates of Scopulariopsis brevicaulis].
Carrillo-Muñoz AJ; Cárdenes CD; Carrillo-Orive B; Rodríguez V; Del Valle O; Casals JB; Ezkurra PA; Quindós G
Rev Iberoam Micol; 2005 Jun; 22(2):110-3. PubMed ID: 16107170
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of aminosterols against dermatophytes.
Coulibaly O; Alhanout K; L'Ollivier C; Brunel JM; Thera MA; Djimdé AA; Doumbo OK; Piarroux R; Ranque S
Med Mycol; 2013 Apr; 51(3):309-12. PubMed ID: 22998181
[TBL] [Abstract][Full Text] [Related]
26. Antifungal susceptibility testing of Trichophyton rubrum by E-test.
da Silva Barros ME; de Assis Santos D; Soares Hamdan J
Arch Dermatol Res; 2007 May; 299(2):107-9. PubMed ID: 17333224
[TBL] [Abstract][Full Text] [Related]
27. Antifungal susceptibilities of dermatophytic agents isolated from clinical specimens.
Cetinkaya Z; Kiraz N; Karaca S; Kulac M; Ciftci IH; Aktepe OC; Altindis M; Kiyildi N; Piyade M
Eur J Dermatol; 2005; 15(4):258-61. PubMed ID: 16048753
[TBL] [Abstract][Full Text] [Related]
28. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
Oz Y; Akşit F; Kiraz N; Kiremitçi A
Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574
[TBL] [Abstract][Full Text] [Related]
29. Comparison between the standardized clinical and laboratory standards institute M38-A2 method and a 2,3-Bis(2-Methoxy-4-Nitro-5-[(Sulphenylamino)Carbonyl]-2H-tetrazolium hydroxide- based method for testing antifungal susceptibility of dermatophytes.
Shehata AS; Mukherjee PK; Ghannoum MA
J Clin Microbiol; 2008 Nov; 46(11):3668-71. PubMed ID: 18832129
[TBL] [Abstract][Full Text] [Related]
30. In vitro antifungal susceptibility of Trichophyton violaceum isolated from tinea capitis patients.
Deng S; de Hoog GS; Verweij PE; Zoll J; Ilkit M; Morsali F; Abliz P; Wang X; Zhan P; Yang L; Hasimu H; Liao W; Pan W; Seyedmousavi S
J Antimicrob Chemother; 2015 Apr; 70(4):1072-5. PubMed ID: 25492394
[TBL] [Abstract][Full Text] [Related]
31. Molecular characterization and antifungal susceptibility profile of dermatophytes isolated from scalp dermatophyte carriage in primary school children in Arak city, Center of Iran.
Allahdadi M; Hajihossein R; Kord M; Rahmati E; Amanloo S; Didehdar M
J Mycol Med; 2019 Apr; 29(1):19-23. PubMed ID: 30660447
[TBL] [Abstract][Full Text] [Related]
32. Lack of cross-hepatotoxicity between fluconazole and voriconazole.
Spellberg B; Rieg G; Bayer A; Edwards JE
Clin Infect Dis; 2003 Apr; 36(8):1091-3. PubMed ID: 12684933
[No Abstract] [Full Text] [Related]
33. Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.
Pfaller MA; Diekema DJ; Colombo AL; Kibbler C; Ng KP; Gibbs DL; Newell VA
J Clin Microbiol; 2006 Oct; 44(10):3578-82. PubMed ID: 17021085
[TBL] [Abstract][Full Text] [Related]
34. Disk diffusion susceptibility testing of dermatophytes with imidazoles.
Venugopal PV; Venugopal TV
Indian J Pathol Microbiol; 1995 Oct; 38(4):369-74. PubMed ID: 9726146
[TBL] [Abstract][Full Text] [Related]
35. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
Kaya AD; Kiraz N
Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
[TBL] [Abstract][Full Text] [Related]
36. In vitro susceptibility patterns of Aspergillus and Fusarium species isolated from equine ulcerative keratomycosis cases in the midwestern and southern United States with inclusion of the new antifungal agent voriconazole.
Pearce JW; Giuliano EA; Moore CP
Vet Ophthalmol; 2009; 12(5):318-24. PubMed ID: 19751493
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic options for the treatment of tinea capitis: griseofulvin versus fluconazole.
Dastghaib L; Azizzadeh M; Jafari P
J Dermatolog Treat; 2005 Feb; 16(1):43-6. PubMed ID: 15897167
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity of new azoles luliconazole and lanoconazole compared with ten other antifungal drugs against clinical dermatophyte isolates.
Baghi N; Shokohi T; Badali H; Makimura K; Rezaei-Matehkolaei A; Abdollahi M; Didehdar M; Haghani I; Abastabar M
Med Mycol; 2016 Oct; 54(7):757-63. PubMed ID: 27118804
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents.
Liu P; Zhu S; Li P; Xie W; Jin Y; Sun Q; Wu Q; Sun P; Zhang Y; Yang X; Jiang Y; Zhang D
Bioorg Med Chem Lett; 2008 Jun; 18(11):3261-5. PubMed ID: 18467095
[TBL] [Abstract][Full Text] [Related]
40. Triazole derivatives with antifungal activity: a pharmacophore model study.
Nowaczyk A; Modzelewska-Banachiewicz B
Acta Pol Pharm; 2008; 65(6):795-8. PubMed ID: 19172871
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
